Current/ Expected Orderbook/ Pending Orders?

The document does not explicitly mention the current or expected order book or pending orders for Insecticides (India) Limited. However, it reflects a positive outlook on demand due to good rainfall and extended sowing seasons leading to higher market opportunities. The company expects strong sales growth, especially in premium products (Focus Maharatna and Maharatna). Volume growth of 15%-20% and value growth near 10% are anticipated for the fiscal year. The business is witnessing good demand in B2C segments, while B2B faces challenges but expects recovery with margin improvements. New produc

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The Company is investing in expansion projects such as the Sotanala project (CAPEX ~100 crores) and a new plant in Dahej (~150 crores CAPEX) funded internally. The Dahej plant commissioning is pending government approvals; production is expected to start soon. The focus appears to be on internal cash flows and operational efficiencies rather than external fundraising. No specific details were shared about issuing new equity or taking on new debt during the call.

Any current/future capex/capital investment/strategic investment?

The company has a CAPEX plan of around ₹100 crore for the Sotanala project in Behror, Rajasthan, where it will build formulation and technical facilities for insecticides and fungicides. This project is expected to be completed in 1 to 1.5 years. Expansion of the formulation facility in Dahej is planned to support volume growth, for which permissions are already obtained. A new plant in Dahej called the L&T plant has been constructed with an investment of over ₹105 crore, doubling technical synthesis capacity. Production is pending state government approval but expected soon, with the plant

Future growth expectations in sales/revenue/volumes?

Volume growth for FY25 is expected to be 15% to 20%. Value (revenue) growth anticipated to be near 10% for FY25. Premium products (Focus Maharatna and Maharatna) targeted for strong double-digit growth. Contribution from premium products in Q1 was about 60% of total B2C sales. New products (launched in last 4 years) contribute around 33% of B2C net sales. Continuous launch of 6-7 premium products annually, mostly patent-protected mixtures. Expected growth in premium segment revenue from ₹800 crore (last fiscal) to ₹1,000 crore (current fiscal). Long-term margin improvement goal to reach 75% co

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a healthy volume growth of 15% to 20% in the current fiscal year. Revenue growth is anticipated to be in the double-digit range, though not much higher than that (around 10%). EBITDA margin improvement is expected, with a current increase of about 300 basis points and a forecasted growth of approximately 100 basis points per annum going forward. EBITDA margin for the full year is expected to remain in double digits, possibly close to or surpassing 11%, contingent on favorable monsoon and crop conditions. Profitability growth is projected to improve from a previous negative

Insecticid.IndiaQ1 FY25Fertilizers & Agrochemicals

Insecticid.India Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹569P/E: 14.0Market Cap: ₹1.8K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Volume growth for FY25 is expected to be 15% to 20%.
Value (revenue) growth anticipated to be near 10% for FY25.
Premium products (Focus Maharatna and Maharatna) targeted for strong double-digit growth.
Contribution from premium products in Q1 was about 60% of total B2C sales.
New products (launched in last 4 years) contribute around 33% of B2C net sales.
Continuous launch of 6-7 premium products annually, mostly patent-protected mixtures.
Expected growth in premium segment revenue from ₹800 crore (last fiscal) to ₹1,000 crore (current fiscal).
Long-term margin improvement goal to reach 75% contribution from premium products in 3-4 years.
Dahej plant expected to add ₹250–₹300 crore revenue potential next year.
Seasonality: Q1 and Q2 are strongest quarters; Q3 and Q4 have lower sales volumes.

Margin guidance

Category 1

The company expects a healthy volume growth of 15% to 20% in the current fiscal year.
Revenue growth is anticipated to be in the double-digit range, though not much higher than that (around 10%).
EBITDA margin improvement is expected, with a current increase of about 300 basis points and a forecasted growth of approximately 100 basis points per annum going forward.
EBITDA margin for the full year is expected to remain in double digits, possibly close to or surpassing 11%, contingent on favorable monsoon and crop conditions.
Profitability growth is projected to improve from a previous negative 7% to a positive 10% this year.
The company is focused on growing its premium products (Focus Maharatna and Maharatna) which currently contribute significantly to margins and profitability.
Continued product premiumization and internal production efficiencies, such as backward integration, are expected to drive margin expansion and earnings growth.

See what Insecticid.India management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
The Company is investing in expansion projects such as the Sotanala project (CAPEX ~100 crores) and a new plant in Dahej (~150 crores CAPEX) funded internally.
The Dahej plant commissioning is pending government approvals; production is expected to start soon.
The focus appears to be on internal cash flows and operational efficiencies rather than external fundraising.
No specific details were shared about issuing new equity or taking on new debt during the call.

Order book

The document does not explicitly mention the current or expected order book or pending orders for Insecticides (India) Limited.
However, it reflects a positive outlook on demand due to good rainfall and extended sowing seasons leading to higher market opportunities.
The company expects strong sales growth, especially in premium products (Focus Maharatna and Maharatna).
Volume growth of 15%-20% and value growth near 10% are anticipated for the fiscal year.
The business is witnessing good demand in B2C segments, while B2B faces challenges but expects recovery with margin improvements.
New product launches and capacity expansions (Sotanala and Dahej plants) are expected to support future order fulfillment and growth.
Overall, the company remains optimistic about the crop protection industry's outlook and sales momentum for the coming quarters.

See what Insecticid.India management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has a CAPEX plan of around ₹100 crore for the Sotanala project in Behror, Rajasthan, where it will build formulation and technical facilities for insecticides and fungicides. This project is expected to be completed in 1 to 1.5 years.
Expansion of the formulation facility in Dahej is planned to support volume growth, for which permissions are already obtained.
A new plant in Dahej called the L&T plant has been constructed with an investment of over ₹105 crore, doubling technical synthesis capacity. Production is pending state government approval but expected soon, with the plant likely starting operations within a month.
This Dahej plant will enable backward integration for certain intermediates, helping reduce costs and stabilize manufacturing.
The Dahej plant has a revenue potential of ₹250-300 crore starting next fiscal but may partly serve internal consumption.
Continuous investments are being made in technology, R&D, and premium product launches.

Track Insecticid.India — get its next earnings analysis in your feed

How does Insecticid.India rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisInsecticid.India

Rev 3Mar 1

See where Insecticid.India sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Insecticid.India rank in Fertilizers & Agrochemicals?

Compare Insecticid.India against every Fertilizers & Agrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Insecticid.India's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Advance Agrolife Ltd (Q4 FY26)
Q4 FY26 total revenue: ₹1,259.07 million, up 40% YoY (Page 24). Key concall takeaways from Advance Agrolife Ltd's Q4 FY26 earnings call — and how it ranks…
Advance Agrolife Ltd (Q1 FY27)
Q1 FY27 revenue from operations: ₹3,304 million, a 96% year-on-year (YoY) increase (Page 23, 25, 22). Key concall takeaways from Advance Agrolife Ltd's Q1 FY27…
Bhagiradha Chemicals & Industries Ltd (Q4 FY26)
158.1 crores . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Bhagiradha Chemicals & Industries Ltd (Q1 FY27)
195.0 crore . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →